Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' EBIT Margin rose 297400.0% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.7%, marking a year-over-year increase of 66000.0%. This contributed to the annual value of 0.1% for FY2024, which is 95500.0% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' EBIT Margin is 15.91%, which was up 297400.0% from 6.57% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBIT Margin registered a high of 27.19% during Q1 2021, and its lowest value of 38.94% during Q4 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median EBIT Margin value was 3.74% (recorded in 2024), while the average stood at 1.32%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 429400bps in 2021, then plummeted by -569600bps in 2022.
  • Ani Pharmaceuticals' EBIT Margin (Quarter) stood at 38.94% in 2021, then surged by 105bps to 1.93% in 2022, then soared by 165bps to 5.11% in 2023, then tumbled by -145bps to 2.3% in 2024, then skyrocketed by 792bps to 15.91% in 2025.
  • Its EBIT Margin stands at 15.91% for Q3 2025, versus 6.57% for Q2 2025 and 13.29% for Q1 2025.